Medline (NASDAQ:MDLN) Upgraded at Zacks Research

Medline (NASDAQ:MDLN) was upgraded by research analysts at Zacks Research to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the company. The Goldman Sachs Group began coverage on Medline in a report on Monday. They issued a “buy” rating and a $49.00 target price on the stock. Bank of America began coverage on shares of Medline in a research note on Monday. They issued a “buy” rating and a $50.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Medline in a report on Monday. They set a “buy” rating and a $50.00 price objective for the company. BNP Paribas started coverage on shares of Medline in a report on Monday. They issued a “neutral” rating and a $38.00 target price on the stock. Finally, Leerink Partners began coverage on Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Medline presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.70.

Medline Price Performance

MDLN stock opened at $43.41 on Tuesday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $45.50.

Insiders Place Their Bets

In other Medline news, Director Charles N. Mills acquired 2,579,310 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the transaction, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the transaction, the insider owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. This trade represents a 55.88% decrease in their position. The SEC filing for this sale provides additional information.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline raised roughly $7.2 billion in its IPO and analysts quickly launched coverage, which is supporting buying interest and secondary market liquidity. Medline Shares Climb as Analysts Launch Coverage After $7.2 Billion IPO
• Positive Sentiment: UBS initiated coverage with a “buy” rating and a $48 price target (about a mid‑teens upside from current levels), giving investors a clear upside case and a visible benchmark for valuation. UBS coverage (reported)
• Positive Sentiment: Multiple major banks (JPMorgan, Citigroup, Barclays, Wells Fargo, Jefferies, Deutsche Bank, TD Cowen, Mizuho, Wolfe Research, Rothschild/Redburn and others) have initiated coverage over the last 24 hours — broad analyst interest typically improves discoverability and can attract institutional orders. JPMorgan coverage (example)
• Neutral Sentiment: Market commentary highlights MDLN as a fresh IPO for long‑term investors, but notes that early post‑IPO performance depends on execution and margin trends rather than headline demand alone. MarketBeat feature
• Neutral Sentiment: BNP Paribas has a “hold” rating — not a sell signal, but a reminder some analysts view near‑term upside as limited until Medline proves post‑IPO execution and growth targets. BNP Paribas hold (reported)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.